Skip to main content
Access every election story that matters
Enjoy unlimited digital access
per week for 24 weeks
Access every election story that matters
Enjoy unlimited digital access
per week
for 24 weeks
// //

Biomarin Pharmaceuticals NASDAQ: BMRN-Q

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Today's Trading

Day Low 76.40
Day High 77.98
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.


Market Capitalization, $K
Shares Outstanding, K
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio


Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

Moderate Buy


A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.


What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.


A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioMarin Pharmaceutical Inc. - BMRN
- PR Newswire - PRF - Thu Sep 9, 8:03PM CDT
PR Newswire - PRF - CMTX
Thu Sep 9, 8:03PM CDT
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN). Such investors are advised to contact at or 888-476-6529, ext. 7980.
Phenylketonuria Drugs Market- Demand, Trends, Share,Global Demand Analysis and Opportunity Outlook 2029
- AmericaNewsHour - Wed Sep 8, 1:26AM CDT
AmericaNewsHour - CMTX
Wed Sep 8, 1:26AM CDT
Research Nester published a report titled  which delivers detailed overview of the global phenylketonuria drugs market in terms of market segmentation by drug type, route of administration, end users, and by region.
U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings
- PR Newswire - PRF - Mon Sep 6, 1:00AM CDT
PR Newswire - PRF - CMTX
Mon Sep 6, 1:00AM CDT
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the U.S Food and Drug Administration (FDA) placed a clinical hold on the BMN 307 Phearless Phase 1/2 study.  The Phearless study is evaluating BMN 307, an investigational AAV5-phenylalanine hydroxylase (PAH) gene therapy, in adults with phenylketonuria (PKU).  The FDA's clinical hold was based on interim safety findings from a pre-clinical, non-GLP pharmacology study.  
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 74.65 +4.17% increase
on 08/20/21
Period Open:76.36
Price movement based on the high, low and last over the given period.
85.28 -8.82% decrease
on 09/01/21
+1.40 (+1.83%) increase
since 08/17/21
3-Month 73.95 +5.15% increase
on 08/16/21
Period Open:82.98
Price movement based on the high, low and last over the given period.
86.33 -9.93% decrease
on 06/28/21
-5.22 (-6.29%) decrease
since 06/17/21
52-Week 71.65 +8.53% increase
on 11/03/20
Period Open:78.36
Price movement based on the high, low and last over the given period.
92.57 -15.99% decrease
on 12/17/20
-0.60 (-0.77%) decrease
since 09/17/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies